Anti-GP2 IgA autoantibodies are associated with poor survival and cholangiocarcinoma in primary sclerosing cholangitis
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Pancreatic autoantibodies (PABs), comprising antibodies against glycoprotein 2 (anti-GP2), are typically associated with complicated phenotypes in Crohn's disease, but have also been observed with variable frequencies in patients with UC. In a previous study, we observed a high frequency of primary sclerosing cholangitis (PSC) in patients with anti-GP2-positive UC. We therefore aimed to characterise the role of anti-GP2 in PSC. DESIGN: In an evaluation phase, sera from 138 well-characterised Norwegian patients with PSC were compared with healthy controls (n=52), and patients with UC without PSC (n=62) for the presence of PABs by indirect immunofluorescence. Further, 180 German patients with PSC served as a validation cohort together with 56 cases of cholangiocarcinoma without PSC, 20 of secondary sclerosing cholangitis (SSC) and 18 of autoimmune hepatitis. RESULTS: Anti-GP2 IgA specifically occurred at considerable rates in large bile duct diseases (cholangiocarcinoma=36%, PSC and SSC about 50%). In PSC, anti-GP2 IgA consistently identified patients with poor survival during follow-up (Norwegian/German cohort: p Log Rank=0.016/0.018). Anti-GP2 IgA was associated with the development of cholangiocarcinoma in both PSC cohorts, yielding an overall OR of cholangiocarcinoma in patients with anti-GP2 IgA-positive PSC of 5.0 (p=0.001). Importantly, this association remained independent of disease duration, bilirubin level and age. CONCLUSIONS: Anti-GP2 IgA can be hypothesised as a novel marker in large bile duct diseases. In particular, in PSC, anti-GP2 IgA identified a subgroup of patients with severe phenotype and poor survival due to cholangiocarcinoma. Anti-GP2 IgA may therefore be a clinically valuable tool for risk stratification in PSC.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“IgA antibodies against glycoprotein 2 have been observed in approximately 50% of people with PSC independent of the presence of IBD; these antibodies may identify a subgroup of patients at increased risk of CCA 49,50 and decreased transplantfree survival.49”
From EASL Clinical Practice Guidelines on sclerosing cholangitis (2022) · cites this paper as [50]
Citations
Cites
Satsangi, J., Silverberg, M. S., Vermeire, S., & Colombel, J.-F. (2006) · Gut · doi:10.1136/gut.2005.082909 · Cited by 3,176
EASL Clinical Practice Guidelines: management of cholestatic liver diseases
European Association for the Study of the Liver (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.04.009 · Cited by 1,729
Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis.
Broomé, U., Olsson, R., Lööf, L., Bodemar, G., Hultcrantz, R., Danielsson, A., Prytz, H., Sandberg-Gertzén, H., Wallerstedt, S., & Lindberg, G. (1996) · Gut · doi:10.1136/gut.38.4.610 · Cited by 819
PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis
Loftus, E. V., Harewood, G. C., Loftus, C. G., Tremaine, W. J., Harmsen, W. S., Zinsmeister, A. R., Jewell, D. A., & Sandborn, W. J. (2005) · Gut · doi:10.1136/gut.2004.046615 · Cited by 777
Hepatic and extrahepatic malignancies in primary sclerosing cholangitis
Bergquist, A., Ekbom, A., Olsson, R., Kornfeldt, D., Lööf, L., Danielsson, Å., Hultcrantz, R., Lindgren, S., Prytz, H., Sandberg-Gertzén, H., et al. (2002) · Journal of Hepatology · doi:10.1016/s0168-8278(01)00288-4 · Cited by 717
Uptake through glycoprotein 2 of FimH+ bacteria by M cells initiates mucosal immune response
Hase, K., Kawano, K., Nochi, T., Pontes, G. S., Fukuda, S., Ebisawa, M., Kadokura, K., Tobe, T., Fujimura, Y., Kawano, S., et al. (2009) · Nature · doi:10.1038/nature08529 · Cited by 632
Primary sclerosing cholangitis
Hirschfield, G. M., Karlsen, T. H., Lindor, K. D., & Adams, D. H. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60096-3 · Cited by 592
Self-citationFickert, P., Fuchsbichler, A., Wagner, M., Zollner, G., Kaser, A., Tilg, H., Krause, R., Lammert, F., Langner, C., Zatloukal, K., et al. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.04.009 · Cited by 468
A Revised Natural History Model for Primary Sclerosing Cholangitis
KIM, W. R., THERNEAU, T. M., WIESNER, R. H., POTERUCHA, J. J., BENSON, J. T., MALINCHOC, M., LARUSSO, N. F., LINDOR, K. D., & DICKSON, E. R. (2000) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(11)64614-4 · Cited by 434
A revised natural history model for primary sclerosing cholangitis.
Kim, W., Therneau, T., Wiesner, R., Poterucha, J. J., Benson, J., Malinchoc, M., LaRusso, N., Lindor, K., & Dickson, E. (1997) · Mayo Clinic proceedings · doi:10.4065/75.7.688 · Cited by 417
Cited by
Primary sclerosing cholangitis – a comprehensive review
Karlsen, T. H., Folseraas, T., Thorburn, D., & Vesterhus, M. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.07.022 · Cited by 868
Self-citationWeismüller, T. J., Trivedi, P. J., Bergquist, A., Imam, M., Lenzen, H., Ponsioen, C. Y., Holm, K., Gotthardt, D., Färkkilä, M. A., Marschall, H.-U., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.02.038 · Cited by 533
Self-citationEASL Clinical Practice Guidelines on sclerosing cholangitis
Chazouilleres, O., Beuers, U., Bergquist, A., Karlsen, T. H., Levy, C., Samyn, M., Schramm, C., & Trauner, M. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.05.011 · Cited by 419
Self-citationAlterations of the bile microbiome in primary sclerosing cholangitis
Liwinski, T., Zenouzi, R., John, C., Ehlken, H., Rühlemann, M. C., Bang, C., Groth, S., Lieb, W., Kantowski, M., Andersen, N., et al. (2020) · Gut · doi:10.1136/gutjnl-2019-318416 · Cited by 149
Self-citationThe Microbiome in Primary Sclerosing Cholangitis: Current Evidence and Potential Concepts
Hov, J., & Karlsen, T. (2017) · Seminars in Liver Disease · doi:10.1055/s-0037-1608801 · Cited by 65
Self-citation
Metadata
- Authors
- Jendrek, S. T., Gotthardt, D., Nitzsche, T., Widmann, L., Korf, T., Michaels, M. A., Weiss, K.-H., Liaskou, E., Vesterhus, M., Karlsen, T. H., Mindorf, S., Schemmer, P., Bär, F., Teegen, B., Schröder, T., Ehlers, M., Hammers, C. M., Komorowski, L., Lehnert, H., Fellermann, K., Derer, S., Hov, J. R., & Sina, C.
- Affiliations
- University of Lübeck (DE)
- University Hospital Heidelberg (DE)
- Euroimmun Medizinische Labordiagnostika (Germany) (DE)
- NIHR Birmingham Liver Biomedical Research Unit (GB)
- Oslo University Hospital (NO)
- Corresponding author
- Sina, Christian
- ORCID
- Venue
- Gut
- Publisher
- BMJ
- Published
- 2016-07-12
- Volume
- 66
- Issue
- 1
- Pages
- 137-144
- ISSN
- 0017-5749 (ISSN-L)
- 1468-3288
- OpenAlex
- W2467158996
- Cited by
- 83
- References
- 38
- Citations by year
- 2026: 8 · 2025: 9 · 2024: 11 · 2023: 5 · 2022: 7 · 2021: 8 · 2020: 6 · 2019: 11 · 2018: 7 · 2017: 9 · 2016: 2
- FWCI
- 6.99
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- other-oa
- Locations
- Gut (publishedVersion)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
- NORA - Norwegian Open Research Archives (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
- Health Sciences › Medicine › Rheumatology › IgG4-Related and Inflammatory Diseases
- Keywords
- GP2, primary sclerosing cholangitis, cholangiocarcinoma, pancreatic autoantibodies, secondary sclerosing cholangitis, autoimmune hepatitis, survival, risk stratification, inflammatory bowel disease
- MeSH terms
- Adolescent, Adult, Aged, Autoantibodies, Bile Duct Neoplasms, Cell Transformation, Neoplastic, Colitis, Ulcerative, Female, Humans, Immunoglobulin A, Male, Middle Aged, Retrospective Studies, Risk Factors, Time Factors, Cholangitis, Sclerosing, Biomarkers, Survival Rate, Case-Control Studies, Cholangiocarcinoma, Hepatitis, Autoimmune, Young Adult, GPI-Linked Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Anti-GP2 IgA autoantibodies are associated with poor survival and cholangiocarcinoma in primary sclerosing cholangitis. https://app.cochat.ai/papers/10.1136/gutjnl-2016-311739
- The paper
- Jendrek, S. T., Gotthardt, D., Nitzsche, T., Widmann, L., Korf, T., Michaels, M. A., Weiss, K.-H., Liaskou, E., Vesterhus, M., Karlsen, T. H., Mindorf, S., Schemmer, P., Bär, F., Teegen, B., Schröder, T., Ehlers, M., Hammers, C. M., Komorowski, L., Lehnert, H., . . . Sina, C. (2017). Anti-GP2 IgA autoantibodies are associated with poor survival and cholangiocarcinoma in primary sclerosing cholangitis. Gut. https://doi.org/10.1136/gutjnl-2016-311739
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.